Loxo Oncology Inc. wasn't actively seeking a partner for its two most advanced contenders for the treatment of a rare type of genetically defined cancer but, given the opportunity to nail down a potential $1.55 billion deal with Bayer AG, "we saw the financial and strategic rationale," Jacob Van Naarden, Loxo's chief business officer, told BioWorld.